FTC cracking down on junk patents in drugs like Ozempic

Published



In an attempt to curb inaccurate patent listings in the Food and Drug Administration’s “Orange Book,” a list of drugs the FDA has deemed safe and effective, the Federal Trade Commission has sent warning letters and deemed more than 300 patents unsuitable.

The disputed patents include a junk patent for Ozempic, among other drugs for COPD, diabetes, weight loss, and asthma. Ozempic has been lauded for its weight-loss effects, though some have abused the drug.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.